HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Drug evaluation: CP-751871, a human antibody against type I insulin-like growth factor receptor for the potential treatment of cancer.

Abstract
Several phase II trials of CP-751871 are currently underway, including a phase Ib/II [corrected] trial of CP-751871 in combination with paclitaxel and carboplatin in patients with advanced NSCLC, a phase II trial of CP-751871 in combination with docetaxel and prednisone in patients with hormone-refractory prostate cancer, and a phase II trial of CP-751871 in combination with exemestane in hormone receptor positive advanced breast cancer [corrected]
AuthorsDeepali Sachdev
JournalCurrent opinion in molecular therapeutics (Curr Opin Mol Ther) Vol. 9 Issue 3 Pg. 299-304 (Jun 2007) ISSN: 1464-8431 [Print] England
PMID17608029 (Publication Type: Journal Article)
Chemical References
  • Antibodies
  • Receptors, Somatomedin
  • Carboplatin
  • Paclitaxel
Topics
  • Antibodies (adverse effects, immunology, therapeutic use)
  • Carboplatin (therapeutic use)
  • Clinical Trials, Phase I as Topic
  • Clinical Trials, Phase II as Topic
  • Drug Evaluation, Preclinical
  • Humans
  • Neoplasms (drug therapy)
  • Paclitaxel (therapeutic use)
  • Receptors, Somatomedin (immunology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: